Is ChemoCentryx Inc (ccxi) stock too volatile?
2 Stocks Down 30% in 2022 That Are Great Buys Right Now. A couple of good stocks that have fallen more than 30% in 2022 and could be worth buying today are ChemoCentryx (NASDAQ: CCXI) and Meta ...
How many shares of ccxi stock are being traded today?
Apr 11, 2022 · Real-time trade and investing ideas on ChemoCentryx, Inc. CCXI from the largest community of traders and investors.
What is ChemoCentryx's (CHMC) share price potential in the next year?
Apr 12, 2022 · Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-Industry Biotechnology Sector Medical Current Symbol NASDAQ:CCXI Previous Symbol CUSIP 16383L10 CIK 1340652 Web www.chemocentryx.com Phone (650) 210-2900 Fax 650-210-2910 Employees 133 Year Founded N/A Sales & Book Value Annual Sales $32.22 million Price / Sales 50.51 …
Should you buy ChemoCentryx's (ccxi) tavneos?
ChemoCentryx, Inc.'s stock is down 24%, but insiders still have about US$133k in profit after buying earlier this year Insiders who bought ChemoCentryx, Inc. ( NASDAQ:CCXI ) …
Is CCXI a good investment?
Out of 6 analysts, 2 (33.33%) are recommending CCXI as a Strong Buy, 2 (33.33%) are recommending CCXI as a Buy, 2 (33.33%) are recommending CCXI as a Hold, 0 (0%) are recommending CCXI as a Sell, and 0 (0%) are recommending CCXI as a Strong Sell. What is CCXI's earnings growth forecast for 2022-2024?
Is ChemoCentryx a good investment?
ChemoCentryx finds support from accumulated volume at $22.91 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. This stock has average movements during the day and with good trading volume, the risk is considered to be medium.
Why did CCXI go down?
Shares of ChemoCentryx (NASDAQ: CCXI) suffered an ugly 79% plunge in May, according to data provided by S&P Global Market Intelligence, after a Food and Drug Administration advisory committee offered up a split opinion on the efficacy of avacopan, the biotech's treatment for antineutrophil cytoplasmic autoantibody ( ...Jun 4, 2021
When did CCXI go public?
CCXI's initial public offering (IPO) occurred on February 8, 2012.
Will CCXI go up?
ChemoCentryx Inc (NASDAQ:CCXI) The 8 analysts offering 12-month price forecasts for ChemoCentryx Inc have a median target of 64.50, with a high estimate of 110.00 and a low estimate of 30.00. The median estimate represents a +145.34% increase from the last price of 26.29.
Did FDA approve CCXI?
Oct 8 (Reuters) - ChemoCentryx Inc (CCXI. O) said on Friday the U.S. health agency approved its lead drug for treating a rare, fatal autoimmune disease, sending the biopharmaceutical company's shares up by more than 70%.Oct 8, 2021
Why is ChemoCentryx stock going up?
What happened. Shares of ChemoCentryx ( CCXI 5.50% ) soared 96% on Friday after the biopharmaceutical company received Food and Drug Administration approval for its treatment for a rare autoimmune disease.Oct 8, 2021
Why did ChemoCentryx stock fall?
The drugmaker's shares tanked last year as a result of the protracted regulatory process for its anti-neutrophil cytoplasmic autoantibody (ANCA)-vasculitis medication known as Tavneos (avacopan). ANCA-vasculitis is an autoimmune disorder characterized by swelling and damage to small blood vessels.Jan 12, 2022
Is ChemoCentryx a buy right now?
6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last twelve months. There are curren...
How has ChemoCentryx's stock price been impacted by COVID-19 (Coronavirus)?
ChemoCentryx's stock was trading at $41.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Or...
Are investors shorting ChemoCentryx?
ChemoCentryx saw a decrease in short interest in January. As of January 31st, there was short interest totaling 4,960,000 shares, a decrease of 16....
When is ChemoCentryx's next earnings date?
ChemoCentryx is scheduled to release its next quarterly earnings announcement on Thursday, May 5th 2022. View our earnings forecast for ChemoCentr...
How were ChemoCentryx's earnings last quarter?
ChemoCentryx, Inc. (NASDAQ:CCXI) posted its quarterly earnings results on Tuesday, March, 1st. The biopharmaceutical company reported ($0.58) earni...
What price target have analysts set for CCXI?
6 brokerages have issued 12-month price objectives for ChemoCentryx's shares. Their forecasts range from $38.00 to $110.00. On average, they antici...
Who are ChemoCentryx's key executives?
ChemoCentryx's management team includes the following people: Thomas J. Schall , Chairman, President & Chief Executive Officer Tausif Butt , Chi...
What is Thomas J. Schall's approval rating as ChemoCentryx's CEO?
10 employees have rated ChemoCentryx CEO Thomas J. Schall on Glassdoor.com . Thomas J. Schall has an approval rating of 58% among ChemoCentryx's e...
Who are some of ChemoCentryx's key competitors?
Some companies that are related to ChemoCentryx include Amgen (AMGN) , Gilead Sciences (GILD) , Regeneron Pharmaceuticals (REGN) , Vertex Pharm...
Which institutional investors are selling ChemoCentryx stock?
Which institutional investors are buying ChemoCentryx stock?
CCXI stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Wasatch Advisors Inc., Wells Fargo & Company MN, Susquehanna International Group LLP, Raymond James Financial Services Advisors Inc., Parallax Volatility Advisers L.P., BlackRock Inc., and Integral Health Asset Management LLC.
How do I buy shares of ChemoCentryx?
CCXI stock was bought by a variety of institutional investors in the last quarter, including Pictet Asset Management SA, Millennium Management LLC, Marshall Wace LLP, Sofinnova Investments Inc., GW&K Investment Management LLC, Goldman Sachs Group Inc., Goldman Sachs Group Inc., and Principal Financial Group Inc.. View insider buying and selling activity for ChemoCentryx or or view top insider-buying stocks..
What is ChemoCentryx's stock price today?
Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
How much money does ChemoCentryx make?
One share of CCXI stock can currently be purchased for approximately $28.64.
Where are ChemoCentryx's headquarters?
ChemoCentryx has a market capitalization of $2.00 billion and generates $64.89 million in revenue each year. The biopharmaceutical company earns $-55.36 million in net income (profit) each year or ($1.74) on an earnings per share basis.
How can I contact ChemoCentryx?
ChemoCentryx is headquartered at 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043.
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates
ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at (650) 210-2900, via email at [email protected], or via fax at 650-210-2910.
Lisanti Capital Growth, LLC Buys Saia Inc, Knight-Swift Transportation Holdings Inc, ..
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -30.97% and 3.43%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
ChemoCentryx (CCXI) Tavneos Gets EU Nod for ANCA Vasculitis
Investment company Lisanti Capital Growth, LLC (Current Portfolio) buys Saia Inc, Knight-Swift Transportation Holdings Inc, Cytokinetics Inc, ArcBest Corp, Inspire Medical Systems Inc, sells CommVault Systems Inc, Varonis Systems Inc, Sprout Social Inc, Acadia Healthcare Co Inc, Crocs Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Lisanti Capital Growth, LLC..
Signals & Forecast
Following approval in the EU, ChemoCentryx (CCXI) plans to launch Tavneos for treating ANCA-associated vasculitis in first-half 2022.
Support, Risk & Stop-loss
A buy signal was issued from a pivot bottom point on Thursday, January 27, 2022, and so far it has risen 18.64%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD).
Is ChemoCentryx stock A Buy?
On the downside, the stock finds support just below today's level from accumulated volume at $26.64 and $25.61. There is natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, ChemoCentryx finds support just below today's level at $26.64.
Insiders are very negative selling more shares than they are buying in ChemoCentryx
ChemoCentryx holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
About ChemoCentryx
In the last 100 trades there were 849.09 thousand shares bought and 4.43 million shares sold. The last trade was done 34 days ago by Feczko Joseph M who sold 12.5 thousand shares. In general the insiders are selling more stocks than they buy. There can be a variety of reasons for this, but in general it can be considered as a negative signal.
Golden Star Signal
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders, and cancer in the United States.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Component Grades
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
CCXI POWR Grades
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
CCXI Stock Summary
CCXI scores best on the Growth dimension, with a Growth rank ahead of 88.26% of US stocks.
CCXI Valuation Summary
With a price/sales ratio of 70.53, ChemoCentryx Inc has a higher such ratio than 96.57% of stocks in our set.
CCXI's Quality Factors
CCXI's EV/EBIT ratio is -9.1; this is 131.06% lower than that of the median Healthcare stock.
Latest CCXI News From Around the Web
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
Continue Researching CCXI
Below are the latest news stories about ChemoCentryx Inc that investors may wish to consider to help them evaluate CCXI as an investment opportunity.
Analyst price target for CCXI
Want to do more research on ChemoCentryx Inc's stock and its price? Try the links below:
CCXI earnings per share forecast
Based on 6 analyst s offering 12 month price targets for ChemoCentryx Inc.
CCXI revenue forecast
What is CCXI 's earnings per share in the next 3 years based on estimates from 6 analyst s?
CCXI revenue growth forecast
What is CCXI 's revenue in the next 3 years based on estimates from 6 analyst s?